Intervention | Comparator | ||||
---|---|---|---|---|---|
MTX | Abatacept + MTX | aTNF + MTX | Tocilizumab + MTX | ||
MTX | Estimate | 0 | -4.18 | -5.24 | -4.58 |
95% CrI | (-6.07, -2.27) | (-6.33, -4.16) | (-5.9, -3.27) | ||
P(better) | <1% | <1% | <1% | ||
Abatacept + MTX | Estimate | 4.18 | 0 | -1.08 | -0.41 |
95% CrI | (2.27, 6.07) | (-3.25, 1.11) | (-2.72, 1.87) | ||
P(better) | >99% | 17% | 36% | ||
aTNF + MTX | Estimate | 5.24 | 1.08 | 0 | 0.66 |
95% CrI | (4.16, 6.33) | (-1.11, 3.25) | (-1.04, 2.36) | ||
P(better) | >99% | 83% | 78% | ||
Tocilizumab + MTX | Estimate | 4.58 | 0.41 | -0.66 | 0 |
95% CrI | (3.27, 5.9) | (-1.87, 2.72) | (-2.36, 1.04) | ||
P(better) | >99% | 64% | 22% |